Physician profile
Jay D Haskett
NPI 1730199316
$3,051.60
in general payments reported to CMS, 2019-2025
34 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $500 · 2021: $769 · 2022: $363 · 2023: $393 · 2024: $469 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $540.78 | 2020-2022 | |
| Abbvie INC. | $465.33 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $252.85 | 2020-2025 | Pifeltro, Delstrigo, Capvaxive |
| Gilead Sciences, INC. | $180.13 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $139.49 | 2020-2022 | |
| Glaxosmithkline, LLC. | $127.97 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $111.09 | 2024 | Voquezna |
| Sonex Health, INC. | $98.76 | 2025 | Sx-One Microknife |
| Pfizer INC. | $92.71 | 2022-2025 | |
| Cranial Technologies, INC | $85.43 | 2021-2023 | Doc Band |
| Neurocrine Biosciences, INC. | $81.28 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.60 | 2023-2025 | |
| Lilly USA, LLC | $75.49 | 2020-2025 | Zepbound, Mounjaro |
| Corcept Therapeutics | $65.70 | 2025 | Korlym |
| Abbott Laboratories | $61.23 | 2022-2024 | Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $61.06 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $60.78 | 2022-2024 | Aptima, Thinprep 2000 Processor |
| Viiv Healthcare Company | $53.89 | 2021-2023 | Rukobia |
| Boston Scientific Corporation | $50.27 | 2024-2025 | General - Pain Management |
| Sanofi-Aventis U.S. LLC | $43.90 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $41.12 | 2020-2021 | |
| Exact Sciences Corporation | $38.18 | 2024-2025 | Cologuard Collection Kit |
| Tris Pharma INC | $36.11 | 2020 | |
| Amgen INC. | $33.21 | 2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $30.54 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.71 | 2022 | |
| Fresenius Kabi USA, LLC | $19.39 | 2024 | Idacio |
| Vanda Pharmaceuticals INC. | $18.81 | 2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $16.42 | 2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $14.80 | 2022 | |
| Novo Nordisk INC | $13.82 | 2023 | Rybelsus, Ozempic |
| Qiagen, LLC | $13.49 | 2025 | |
| Dexcom, INC. | $12.43 | 2022 | |
| Theratechnologies INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Haskett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.